Aytu BioPharma, Inc. (AYTU) vs Neuphoria Therapeutics Inc. (NEUP)
A side-by-side comparison of Aytu BioPharma, Inc. and Neuphoria Therapeutics Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
AYTU
Aytu BioPharma, Inc.
$2.06HealthcareDelayed quote: Oct 6, 2026, 2:29 PM EDT
NEUP
Neuphoria Therapeutics Inc.
$3.47HealthcareDelayed quote: Oct 6, 2026, 2:25 PM EDT
Total return — AYTU vs NEUP
growth of $100 · dividends reinvested · last 5yAYTU -93.5% (-42.1%/yr)NEUP -98.0% (-54.5%/yr)AYTU compounded faster over this window
AYTU NEUP
AYTU vs NEUP: by the numbers
- •AYTU is the larger company ($22M vs $19M market cap).
- •Both run net losses; AYTU's is the smaller (-24.76% vs -1578.40% net margin).
- •NEUP grew revenue faster over the past five years (11.12% vs -2.59% CAGR).
Metrics side by side
Valuation
| Metric | AYTU | NEUP |
|---|---|---|
| P/S ratio | 0.38 | 15.95 |
| P/B ratio | 0.63 | 0.76 |
| FCF yield | 14.70% | N/A |
Profitability
| Metric | AYTU | NEUP |
|---|---|---|
| Gross margin | 63.95% | 43.54% |
| Operating margin | -14.44% | -835.53% |
| Net margin | -24.76% | -1578.40% |
| ROE | -40.40% | -75.34% |
| ROIC | -14.21% | -49.83% |
Growth (annualized)
| Metric | AYTU | NEUP |
|---|---|---|
| Revenue CAGR (5Y) | -2.59% | 11.12% |
| Total return CAGR (5Y) | -48.14% | N/A |
Frequently asked
- Which has grown faster, AYTU or NEUP?
- Over the past five years, NEUP grew revenue faster — AYTU at a -2.59% CAGR versus NEUP at 11.12%.
Go deeper
Dig into the metrics
Aytu BioPharma ROENeuphoria Therapeutics ROEAytu BioPharma operating marginNeuphoria Therapeutics operating marginAytu BioPharma revenue growthNeuphoria Therapeutics revenue growthAytu BioPharma free cash flowNeuphoria Therapeutics free cash flow
Aytu BioPharma & Neuphoria Therapeutics appear in these rankings
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.